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Current techniques available to describe the individual T cell
receptor (TCR) repertoire are highly expensive and necessitate spe-
cific computational analysis tools in order to describe the repertoires
qualitatively and quantitatively and to correct sequencing errors.
Montagne et al. [1] in their work propose a new approach to TCR rep-
ertoire sequencing investigation. The diversity of the TCR repertoire
is the result of multiple processes of DNA stochastic somatic recombi-
nation and it is responsible for effective immunity against pathogens.
A TCR molecule is a heterodimer composed of alpha and beta chains
and in humans of a minor population of delta and gamma chains.
These chains are very diverse, because of the imprecise rearrange-
ments of either V and J segments (alpha chain) or V, D and J segments
(beta chain), that determine the non-template addition or removal of
DNA base pairs, resulting in a huge variety of complementary deter-
mining regions (CDR3) and in an extraordinary genomic diversity,
similar only to the ones we find in the antibodies [2]. For many years
it was a challenge to investigate this hypervariable molecule and a
complete description of the TCR repertoire has never been achieved.
Recent advances in high-throughput sequencing (HTS) techniques
paved the way to explore the TCR repertoire dynamics bridging cell-
based methods and computational ones into qualitative and quanti-
tative receptor description [3] and antigen discovery [4]. Of note, HTS
is not as accurate as Sanger sequencing and introduces errors during
library amplification and/or during sequencing [5], therefore, several
expensive strategies and different algorithms have been developed
to attenuate the impact of errors on the TCR repertoire analysis and
on the consequent biological data interpretation [6,7]. In their work,
Montagne et al. developed an original experimental pipeline to
sequence TCR and analyze CDR3 repertoire, dropping the cost (from a
mean of $500$1000 to $20 per sample) for primers and for unique
molecular identifiers (UMIs) to correct amplification bias. The* Corresponding author.
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seq), is a simplified multiplex PCR-based involving a minimal primer
set targeting the upstream sequence of the complementarity deter-
mining region 3 (CDR3), the framework region 3 (FR3). Authors use
the TCRB FR3 regions, collected from the Immunogenetics reference
directory (IMGT/GENE-DB) [8] for primers design. They individuate
47 distinct 30-sequences of 20 nucleotides (20-mers) that represent
the 128 functional TCRBV alleles in IMGT; using these sequences as
target allows scientists to significantly minimize CDR3 amplicon
length. Therefore, from the selected 47 TCRB FR3 30 20-mers, Mon-
tagne et al. obtained three sets of primers: 1MM set (34 primers),
Compact set (20 primers) and Full set (47 primers) required to multi-
ply CDR3 region of TCR beta chains. The combinations of this experi-
mental pipeline with an algorithm that they have personally
developed, Inferring Sequences via Efficiency Projection and Primer
Incorporation (ISEPPI), permitted the determination of linkage
between CDR3 and corresponding V fragment of the TCR beta chain,
as further verification of FR3AK-seq performance. The accuracy of
ISEPPI was found to be maximal for the Full primer set, ranging
between 67.7 and 72.4% depending on CDR3s clone counts (10 -
100). To verify the reliability of FR3AK-seq technology, the authors
compared their method to two sensitive and quantitative existing
commercial methods specialized in TCR sequencing from adaptive
Biotechnologies and ArcherDX’s and subsequently found no differen-
ces in the performance of FR3AK-seq in terms of CDR3 quantification
and amplification bias. In order to apply this methodology to a
pathology, Montagne et al. analyzed TCR repertoire on a large cohort
of patients with idiopathic inflammatory myopathies (IIMs), an
inflammatory heterogeneous disease in which the pathogenic role of
T cells is still unknown [9], and compared them with healthy donors.
TCR repertoire was successfully described in peripheral blood lym-
phocytes and in muscle infiltrating cells, demonstrating that a cluster
of closely related TCRs is present in muscle from patients with spo-
radic inclusion myositis (IBM).
To summarize, the strategy of targeting the 30 terminus of FR3
successfully allow us to minimize the number of primers and ampli-
con length, while preserving sequencing depth and providing a reli-
able capture of TCR repertoire clonal abundance, comparable to the
currently available industrial sequencing platforms. We believe that
Montagne et al. [1] proposed FR3AK-seq technology may pave the
way to an affordable and reliable TCR sequencing, broadening our
knowledge of the TCR repertoire in disease pathogenesis and
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